FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967226362> ?p ?o ?g. }

• W1967226362 endingPage "71" @default.
• W1967226362 startingPage "67" @default.
• W1967226362 abstract "A stable and sustained suppression of growth hormone (GH) secretion was noted in 101 patients treated long term with individual doses (20 and 30 mg in 89 patients, 40 mg in 12 patients) of Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland). Doses of 20 mg and 30 mg at 4-week intervals delivered average octreotide concentrations of 1,348 +/- 483 ng/L and 2,631 +/- 1,026 ng/L, respectively, in steady-state conditions and provided adequate control of patients who had been well controlled during treatment with 0.1 mg and 0.2 mg thrice-daily subcutaneous (SC) Sandostatin. Suppression of GH serum concentrations to less than 5 micrograms, 2 micrograms, and even 1 microgram/L was recorded in more patients and more consistently during long-term treatment with Sandostatin LAR than Sandostatin. A marked decrease or even a normalization of insulin-like growth factor-1 (IGF-1) serum concentrations was observed after the first double-blind 10-, 20-, or 30-mg dose of Sandostatin LAR. A progressive improvement was recorded during long-term treatment, with normalization of IGF-1 serum concentrations in 65.3% of patients. A marked clinical improvement was observed in parallel, with 36 of 101 patients (35.6%) becoming asymptomatic after the nineteenth injection of Sandostatin LAR. A greater than 20% shrinkage of the GH-secreting adenoma was also recorded in 12 of 14 patients treated with Sandostatin LAR after receiving only 2 to 4 weeks of treatment with SC Sandostatin and in 11 of 18 patients receiving Sandostatin LAR as adjuvant therapy after failure of surgery. The systemic tolerability of Sandostatin LAR was good, and most adverse events were mild and short term (1 to 2 days). No impairment of thyroid function was detected. Newly occurring gallstones were recorded in four of 101 patients and microlithiasis in four of 101 after up to 30 months of treatment with Sandostatin LAR. Due to its excellent efficacy, good tolerability, convenience of administration, and acceptability by patients, Sandostatin LAR is considered a promising therapeutic tool in the management of acromegalic patients." @default.
• W1967226362 created "2016-06-24" @default.
• W1967226362 creator A5012311701 @default.
• W1967226362 creator A5018974244 @default.
• W1967226362 creator A5029716255 @default.
• W1967226362 creator A5037611057 @default.
• W1967226362 creator A5041052589 @default.
• W1967226362 creator A5049719396 @default.
• W1967226362 creator A5062762892 @default.
• W1967226362 creator A5066559878 @default.
• W1967226362 creator A5071721348 @default.
• W1967226362 creator A5083229910 @default.
• W1967226362 creator A5084175938 @default.
• W1967226362 creator A5090367243 @default.
• W1967226362 date "1996-08-01" @default.
• W1967226362 modified "2023-10-18" @default.
• W1967226362 title "Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients" @default.
• W1967226362 cites W1968641918 @default.
• W1967226362 cites W2104570808 @default.
• W1967226362 doi "https://doi.org/10.1016/s0026-0495(96)90087-6" @default.
• W1967226362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8769387" @default.
• W1967226362 hasPublicationYear "1996" @default.
• W1967226362 type Work @default.
• W1967226362 sameAs 1967226362 @default.
• W1967226362 citedByCount "141" @default.
• W1967226362 countsByYear W19672263622012 @default.
• W1967226362 countsByYear W19672263622013 @default.
• W1967226362 countsByYear W19672263622014 @default.
• W1967226362 countsByYear W19672263622015 @default.
• W1967226362 countsByYear W19672263622016 @default.
• W1967226362 countsByYear W19672263622017 @default.
• W1967226362 countsByYear W19672263622018 @default.
• W1967226362 countsByYear W19672263622019 @default.
• W1967226362 countsByYear W19672263622020 @default.
• W1967226362 countsByYear W19672263622022 @default.
• W1967226362 crossrefType "journal-article" @default.
• W1967226362 hasAuthorship W1967226362A5012311701 @default.
• W1967226362 hasAuthorship W1967226362A5018974244 @default.
• W1967226362 hasAuthorship W1967226362A5029716255 @default.
• W1967226362 hasAuthorship W1967226362A5037611057 @default.
• W1967226362 hasAuthorship W1967226362A5041052589 @default.
• W1967226362 hasAuthorship W1967226362A5049719396 @default.
• W1967226362 hasAuthorship W1967226362A5062762892 @default.
• W1967226362 hasAuthorship W1967226362A5066559878 @default.
• W1967226362 hasAuthorship W1967226362A5071721348 @default.
• W1967226362 hasAuthorship W1967226362A5083229910 @default.
• W1967226362 hasAuthorship W1967226362A5084175938 @default.
• W1967226362 hasAuthorship W1967226362A5090367243 @default.
• W1967226362 hasConcept C126322002 @default.
• W1967226362 hasConcept C134018914 @default.
• W1967226362 hasConcept C185592680 @default.
• W1967226362 hasConcept C202751555 @default.
• W1967226362 hasConcept C2776297358 @default.
• W1967226362 hasConcept C2777288759 @default.
• W1967226362 hasConcept C2777433750 @default.
• W1967226362 hasConcept C2777910003 @default.
• W1967226362 hasConcept C2781025020 @default.
• W1967226362 hasConcept C2984496839 @default.
• W1967226362 hasConcept C51296783 @default.
• W1967226362 hasConcept C55493867 @default.
• W1967226362 hasConcept C71315377 @default.
• W1967226362 hasConcept C71924100 @default.
• W1967226362 hasConcept C90924648 @default.
• W1967226362 hasConceptScore W1967226362C126322002 @default.
• W1967226362 hasConceptScore W1967226362C134018914 @default.
• W1967226362 hasConceptScore W1967226362C185592680 @default.
• W1967226362 hasConceptScore W1967226362C202751555 @default.
• W1967226362 hasConceptScore W1967226362C2776297358 @default.
• W1967226362 hasConceptScore W1967226362C2777288759 @default.
• W1967226362 hasConceptScore W1967226362C2777433750 @default.
• W1967226362 hasConceptScore W1967226362C2777910003 @default.
• W1967226362 hasConceptScore W1967226362C2781025020 @default.
• W1967226362 hasConceptScore W1967226362C2984496839 @default.
• W1967226362 hasConceptScore W1967226362C51296783 @default.
• W1967226362 hasConceptScore W1967226362C55493867 @default.
• W1967226362 hasConceptScore W1967226362C71315377 @default.
• W1967226362 hasConceptScore W1967226362C71924100 @default.
• W1967226362 hasConceptScore W1967226362C90924648 @default.
• W1967226362 hasLocation W19672263621 @default.
• W1967226362 hasLocation W19672263622 @default.
• W1967226362 hasOpenAccess W1967226362 @default.
• W1967226362 hasPrimaryLocation W19672263621 @default.
• W1967226362 hasRelatedWork W1965212674 @default.
• W1967226362 hasRelatedWork W1996610858 @default.
• W1967226362 hasRelatedWork W2043351056 @default.
• W1967226362 hasRelatedWork W2070270823 @default.
• W1967226362 hasRelatedWork W2076991536 @default.
• W1967226362 hasRelatedWork W2090676128 @default.
• W1967226362 hasRelatedWork W2336761926 @default.
• W1967226362 hasRelatedWork W2428581338 @default.
• W1967226362 hasRelatedWork W335658123 @default.
• W1967226362 hasRelatedWork W385667733 @default.
• W1967226362 hasVolume "45" @default.
• W1967226362 isParatext "false" @default.
• W1967226362 isRetracted "false" @default.
• W1967226362 magId "1967226362" @default.
• W1967226362 workType "article" @default.